Kaken Pharmaceutical
As of the edition of 20 October 2026, Kaken Pharmaceutical runs 6 drugs, 4 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 1 |
| Total | 6 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ethambutol | none listed | 0 |
| Sofpironium | Ends 2040 (patent) | 5 |
| Efinaconazole | none listed | 0 |
| Trafermin | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| FGFR2 Fibroblast growth factor receptor 2 | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Kaken Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Mouth and teeth: 4 trials led
- Inherited and neonatal: 2 trials led
- Blood and lymph: 1 trials led